8-K filing — Transcode Therapeutics, Inc. (RNAZ)
Filed: 2026-10-28 AccNo: 0001104659-26-119658 Size: 207 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
TransCode Therapeutics Announces Updated Clinical Data From Phase 1a Clinical Trial Of TTX-MC138, Reinforcing Evidence Of Antitumor Activity In Heavily Pretreated Patients With Advanced Solid Tumors
Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumorsIn the 14 efficacy-evaluable patients:71.4% stable disease rate57.1% of patients had disease
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
TransCode Therapeutics To Present Poster Featuring TTX-MC138 ESMO Congress 2026
Poster presentation to highlight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumors
Natera, TransCode Therapeutics Partnering To Support Enrollment For TransCode’s Phase 2a Study Of TTX-MC138 In Participants With Colorectal Cancer
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for